Heart-Safe Coordination Compounds for Targeted Breast Cancer Therapy: A Translational Study of Anticancer Efficacy, Cardiotoxicity, and Molecular Mechanisms

https://doi.org/10.66715/ijcar/2025.v1.i1.1737 Original Research | 2025 | Volume 1 | Issue 1 | Page 17-37

Dr. Amit Thakur, Aadharshila Academy, Jogindernagar, Distt Mandi, Himachal Pradesh 175015

Abstract

Background: Coordination compounds have emerged as promising candidates in targeted cancer therapy because of their tunable chemical structures, selective tumor-targeting capabilities, and diverse mechanisms of action. While platinum-based chemotherapeutic agents remain effective against several malignancies, their clinical utility is frequently limited by dose-dependent cardiotoxicity and systemic adverse effects. Developing heart-safe coordination compounds that maintain potent anticancer activity while minimizing cardiovascular toxicity represents an important therapeutic objective in breast cancer management.

Objective: This translational study aimed to evaluate the anticancer efficacy, cardiotoxicity profile, and molecular mechanisms of novel heart-safe coordination compounds for targeted breast cancer therapy, with an emphasis on improving therapeutic selectivity and cardiovascular safety.

Methods: A preclinical translational study was designed using in vitro breast cancer cell models (MCF-7 and MDA-MB-231) and non-tumorigenic cardiomyocyte cell lines to assess selective cytotoxicity. Cell viability, apoptosis induction, reactive oxygen species (ROS) generation, mitochondrial membrane potential, and cell cycle distribution were analyzed using standard biochemical and flow cytometric techniques. Molecular investigations included quantitative PCR, Western blotting, and immunofluorescence to evaluate the expression of apoptosis-, proliferation-, oxidative stress-, and angiogenesis-related biomarkers, including p53, Bax, Bcl-2, caspase-3, Ki-67, VEGF, and Nrf2. Cardiotoxicity was assessed through cardiomyocyte viability assays, oxidative stress markers, mitochondrial integrity, and cardiac injury biomarkers.

Results: The investigated coordination compounds demonstrated significant dose-dependent inhibition of breast cancer cell proliferation while exhibiting substantially lower cytotoxicity toward cardiomyocytes compared with conventional platinum-based agents. Enhanced apoptosis, increased caspase activation, cell cycle arrest, and suppression of angiogenic signaling were observed in treated breast cancer cells. Molecular analyses indicated activation of intrinsic apoptotic pathways, downregulation of anti-apoptotic proteins, and modulation of oxidative stress responses. Importantly, treated cardiomyocytes maintained higher viability, reduced ROS production, preserved mitochondrial function, and significantly lower expression of cardiac injury biomarkers, indicating an improved cardiovascular safety profile.

Conclusion: Heart-safe coordination compounds represent a promising next-generation strategy for targeted breast cancer therapy by combining potent anticancer activity with reduced cardiotoxicity. Their ability to selectively induce tumor cell apoptosis while preserving cardiac cellular integrity highlights their translational potential for safer chemotherapy. Further pharmacokinetic studies, animal investigations, and well-designed clinical trials are warranted to validate their efficacy, safety, and future application in precision oncology.